Figure 5. NUAK1 promotes nuclear translocation of NRF2 in colorectal cancer cell by antagonizing GSK3a. (A, B) Immunoblots of NUAK1-depleted or control colorectal cancer cell ((HCT116-Or (A) and H716 (B)) cytosolic fractions after treatment with oxaliplatin. (C, D) Pretreatment of NUAK1-depleted colorectal cancer cells ((HCT116-Or (C) and H716 (D)) with GSK3β inhibitor BIO-acetoxime (1 μmol/L for 6 hours) restores oxaliplatin-induced NRF2 nuclear translocation.